Form 4: Avidity Biosciences CMO Sells Shares Under 10b5-1 Plan

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, reported the exercise of stock options and subsequent sale of common stock totaling 1,542 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Steven George Hughes, Chief Medical Officer of Avidity Biosciences, Inc., reported transactions involving the company's common stock.
• On September 15, 2025, Hughes exercised stock options to acquire 1,542 shares of common stock at an exercise price of $6.57 per share.
• Concurrently, on September 15, 2025, he sold 1,542 shares of common stock at a price of $45.41 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2024.
• Following these transactions, Hughes beneficially owns 38,867 shares of common stock directly and 49,333 stock options directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it was pre-planned under a 10b5-1 plan, which mitigates negative interpretations. The significant profit margin on the exercised options is a positive for the insider, but the reduction in direct shareholding could be seen as a minor negative for market sentiment.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to insider trading.
• The sale price of $45.41 per share is significantly higher than the exercise price of $6.57 per share, indicating a substantial profit for the insider on these specific shares.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

The stock options held by the reporting person are subject to a vesting schedule, with 1/48th of the total shares vesting monthly from September 11, 2023, until fully vested on the fourth anniversary of the vesting commencement date. The remaining 49,333 stock options will continue to vest according to this schedule until their expiration on September 10, 2033.

Industry Context

Insider transactions, particularly sales, are common across the biotechnology and pharmaceutical industries, especially for executives whose compensation packages often include significant equity components. The use of a Rule 10b5-1 plan is a standard practice to manage personal liquidity while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though mitigated by the 10b5-1 plan. The reduction in direct insider ownership is minor relative to total shares outstanding.
• Management: The Chief Medical Officer realized a profit from equity compensation, which is a standard part of executive compensation.

Next Steps

• Continued vesting of the remaining 49,333 stock options on a monthly basis until September 11, 2027 (fourth anniversary of vesting commencement).
• Potential future transactions under the Rule 10b5-1 plan or other means, subject to SEC reporting requirements.

Key Dates

Recommendation

The filing reports a routine, pre-planned insider transaction (exercise and sale) by a Chief Medical Officer. While an insider sale can sometimes be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic selling. The transaction itself does not provide new fundamental information about Avidity Biosciences' operational performance or future prospects. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive company-specific news or financial results.

Keywords

Avidity Biosciences, RNA, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Steven George Hughes, Chief Medical Officer, 10b5-1 Plan